Produkty 566-97-2

CAS 566-97-2 występuje w naszej ofercie pod nazwami: Zymostenol, >95% (HPLC), Zymostenol, Zymostenol (Standard), Zymostenol, 99.33%. Oferty producentów: TRC, TargetMol, GLPBio, MedChemExpress, Sigma-Aldrich. Dostępne opakowania: 100mg, 10mg, 50mg, 5mg, 25mg, Get quote, 10 mg, 1 mg.

Zymostenol, >95% (HPLC)
TRC
  • opakowanie: 100mg, 10mg, 50mg
  • Warianty: 3
Zobacz produkt
Zymostenol
TargetMol, GLPBio, Sigma-Aldrich
  • opakowanie: 5mg, 10mg, 25mg, 50mg
  • Warianty: 9
od 1046,37
Zobacz produkt
Zymostenol (Standard)
MedChemExpress
  • opakowanie: Get quote
  • Warianty: 1
Zobacz produkt
Zymostenol, 99.33%
MedChemExpress
  • opakowanie: 10 mg, 1 mg, 5 mg
  • Warianty: 3
od 1127,75
Zobacz produkt
Wzór strukturalny: {0} (CAS {1})

(3S,5S,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (CAS 566-97-2) to związek chemiczny o wzorze sumarycznym C27H46O i masie molowej 386.7 g/mol. Nazwa systematyczna IUPAC: (3S,5S,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol. InChIKey: QETLKNDKQOXZRP-XTGBIJOFSA-N.

Dane identyfikacyjne
Wzór sumarycznyC27H46O
Masa molowa386.7 g/mol
Nazwa IUPAC(3S,5S,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
InChIKeyQETLKNDKQOXZRP-XTGBIJOFSA-N
SMILESC[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4)O)C)C

Dane obliczone przez PubChem (NCBI)

Synonimy: Zymostenol, 5alpha-Cholest-8-en-3beta-ol, delta(8)-Cholestenol, 5alpha-Cholest-8(9)-en-3beta-ol, Cholestenol, Cholest-8-en-3-ol, (3beta,5alpha)-, delta8-Cholestenol, 8(9)-cholestenol, zymostenol, (3beta)-, Cholest-8-en-3-ol
Powiązane formy tego związku
(3S,5S,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6,7,7,7-tetradeuterio-6-(trideuteriomethyl)heptan-2-yl]-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol C27H46O
Izomery (ten sam wzór sumaryczny)
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol C27H46O
(3S,5S,9R,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol C27H46O
(3R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol C27H46O
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6,7,7,7-tetradeuterio-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol C27H46O
(3S,5S,9R,10S,13R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol C27H46O
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6,7,7,7-tetradeuterio-6-(trideuteriomethyl)heptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol C27H46O
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol C27H46O
(5R,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one C27H46O
(5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one C27H46O
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-(113C)methyl(4,5,6,7-13C4)heptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol C27H46O
(3S,8S,9S,10R,13R,14S,17R)-2,2,3,4,4,6-hexadeuterio-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-ol C27H46O